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Long non-coding RNAs (lncRNAs) are emerging as important players in biological 
processes in human physiology and disease 1. However, we have limited knowledge 
regarding the involvement of lncRNAs in the development of obesity, type 2 diabetes 
(T2D), and related comorbidities such as nonalcoholic fatty liver disease (NAFLD). NAFLD 
is a complex disease and the molecular mechanism behind the disease progression is not 
well understood. The first and the most benign NAFLD condition is non-alcoholic fatty 
liver (NAFL), or simple steatosis. However, 10-20% of the patients with steatosis will further 
develop non-alcoholic steatohepatitis (NASH), a more severe condition characterized by 
presence of inflammation and hepatocellular injury, which may lead to fibrosis, cirrhosis 
and hepatocellular carcinoma.
In recent years, several studies have identified well-defined mechanisms by which specific 
lncRNAs contribute to the development of NASH fibrosis 2, highlighting their importance 
in disease progression. Based on this evidence, it is clear that a deeper understanding 
of the molecular mechanisms by which lncRNAs contribute to hepatic steatosis, 
inflammation and fibrosis are needed. Furthermore, it is known that the expression of 
lncRNAs is context-specific. It is therefore important to detect the specific cell types in 
which lncRNAs function as well as the stage of disease progression at which disease-
related lncRNAs become dysregulated. 
This thesis aims to address these questions by combing transcriptome profiling in a 
patient cohort, functional genomics of an in vitro model to mimic disease progression and 
follow-up functional studies using various molecular techniques. The research described 
in this thesis highlights the importance of non-coding RNAs in NASH. Firstly, using high-
throughput technology, we show that lncRNAs, similar to protein-coding genes, show 
differential expression between livers of NAFLD patients and normal controls. Secondly, 
we employ functional genomic approaches in human cell lines to further characterize 
selected candidate genes. Going beyond associations, we report that specific lncRNAs 
may drive and regulate key processes in the liver such as hepatocyte apoptosis and 
inflammation. Furthermore, we show that enhancer RNAs (eRNAs) are expressed in the 
liver and show evidence that eRNAs may not only be involved in the regulation of genes 
for liver diseases but may also mediate genetic susceptibility to complex diseases. The 
findings reported in this thesis, together with results from future studies on non-coding 
RNAs and current knowledge of coding genes, should increase our understanding of 
NASH pathogenesis and development, ultimately leading towards better therapeutic 
treatment for NAFL and NASH patients.
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Disease variants and the non-coding genome
Over the last two decades it has been shown that ~98% of the human genome is non-
coding and contains many regulatory elements 3,4. These regions can control mRNA 
levels of protein-coding genes in different ways. The importance of non-coding regions is 
highlighted by genome-wide association studies (GWAS) showing that the vast majority 
(~93%) of reported genetic variants lie in non-coding regions and are enriched for 
regulatory elements such as non-coding RNAs, enhancers, transcription factor binding 
sites and DNase I hypersensitive sites. One of the most prominent research directions 
has been the discovery of genetic variants that can explain variations in gene expression 
levels, which are known as expression quantitative trait loci (eQTLs). These studies have 
offered new promise for understanding the basic processes of gene regulation and for 
interpretation of GWAS. 
Consistent with other disease-associated SNPs, the majority of SNPs associated with 
cardiometabolic diseases affect gene expression levels. Of the 775 cardiometabolic SNPs 
(encompassing 366 independent loci) that we gathered from the Catalog of Published 
Genome-Wide Association studies (https://www.ebi.ac.uk/gwas/), 40% affect expression 
levels of genes located within a 250 kb region of the SNP, based on the blood eQTL 
browser 5, and thereby yielded a list of potential disease-predisposing genes (Chapter 2). 
However, additional analyses are required because eQTLs are frequently tissue-specific in 
their effect, context-dependent and may only be detected after induction or at a specific 
developmental stage 6,7. For example, eQTL tissue-specificity was addressed by Genotype-
Tissue Expression (GTEx) project 7,8. Here, genome-wide analysis in 44 tissues showed 
that eQTLs are significantly enriched for trait associations in relevant pathogenic tissues 
and explain a substantial proportion of the heritability (40–80%) 8. Furthermore, using 
DEPICT pathway analysis 9, we found that 27 genes (loci) are shared between two or more 
traits, showing considerable overlap between the genetic loci associated with different 
cardiometabolic phenotypes, with genes that control lipoprotein metabolism playing a 
central role (Chapter 2). Therefore, we propose a model where there is a strong connection 
between lipid traits and obesity, diabetes-related traits and cardiovascular disease, 
although the genetic connection between diabetes-related traits and cardiovascular 
disease is much weaker. Identifying such patterns helps to pinpoint critical mediators 
influenced by disease-associated variation. 
LncRNAs may contribute to NAFLD progression
Little is known about the role of lncRNAs in the development and progression of NAFLD, 
although growing evidence suggests that these molecules contribute to many of the 
pathophysiological mechanisms underlying the disease. In chapters 3, 4 and 5, we 
identified many lncRNAs associated with different NASH phenotypes and showed that 
some of these lncRNAs may be important players in the disease progression. Several 
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functional studies have been performed to reveal the involvement of lncRNAs in 
controlling hepatocyte viability, liver inflammation and regulation of HNF4A. 
In chapter 3, we identified a novel liver-specific lncRNA, which we named lnc18q22.2 
(HGNC name LIVAR – Liver Cell Viability Associated lncRNA), that showed elevated 
expression in the livers of NASH patients. lnc18q22.2 silencing affects hepatocyte viability 
and, based on our transcriptomic data and cell viability experiments, we hypothesized 
that this lncRNA inhibits hepatocyte apoptosis and necrosis and therefore has a protective 
role in hepatocytes. Hepatocyte cell death by apoptosis (programmed cell death) and/
or necrosis (non-programmed cell death) is increased in patients with NAFLD and in 
experimental models of steatohepatitis. The two fundamental pathways of apoptosis, 
the extrinsic (death receptor-mediated) and intrinsic (organelle-initiated) pathways, are 
involved in NASH 10. Free fatty acids (FFA) induce lipoapoptosis in hepatocytes by activating 
lysosomal pathway of cell death and sensitizing cells to cytokine toxicity 11. Furthermore, 
FFA can stimulate the intrinsic apoptosis pathway via JNK, leading to mitochondrial 
permeabilization, cytochrome c release and caspase activation 12. Inflammatory cytokines 
from visceral adipose tissue or enteric sources further sensitize the liver to oxidative stress 
and cellular injury. For example, TNFα can exacerbate NAFLD by inducing mitochondrial 
reactive oxygen species, by activating stress-related kinases that inhibit insulin signaling 
and promote gluconeogenesis, by suppressing anti-lipogenic effect to compound 
steatosis and by attenuating the anti-inflammatory effects of adiponectin and PPAR-γ 13. 
Other types of programmed cell death, such as necroptosis and pyroptosis, may also play 
a role in NAFLD 14. Notably, there is also crosstalk and/or overlap between the different cell 
death pathways 15. However, we still don’t know in which of these pathways lnc18q22.2 
plays a role. Therefore, the potential mechanism of action needs to be further studied.
Using deep RNA-sequencing in human liver biopsies, we have detected 854 lncRNAs 
associated with NASH (chapter 4). One liver-specific lncRNA, HNF4A-AS1, showed the same 
direction of dysregulation in human and murine NASH. We propose that HNF4A-AS1 plays 
a role in the inflammatory component of NASH development. Knock-down of HNF4A-AS1 
showed an effect on HNF4A expression and on its downstream genes, supporting the idea 
that this lncRNA may regulate HNF4A and its downstream processes. Many studies have 
linked HNF4A function to liver inflammation. HNF4-α represents a central regulator of 
gene transcription in hepatocytes during the acute-phase response 16. HNF4-α has also 
shown sensitivity to the NF-κB pathway, a crucial signaling pathway that dictates cellular 
inflammatory responses 17. Further studies are crucial to confirm the direct link between 
HNF4A-AS1 and HNF4A. 
In chapter 5, we reported 18 lncRNA candidates with unknown function showing 
differential expression between FFA- and TNFα- stimulated HepG2 cells and in the livers 
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of NASH patients. One lncRNA, RP11-91K9.1 (lncTNF), was 20-fold upregulated after 
stimulation with the pro-inflammatory cytokines TNFa and IL1b. Based on our functional 
experiments, this lncRNA may play important role in NF-κB signaling and may regulate 
inflammation in hepatocytes and liver during NASH development. NF-κB is one of the main 
signaling pathways linked to liver inflammation 18,19. Prompt activation of NF-κB is critical 
for host defense against various classes of pathogens. After activation, NF-κB activates 
the expression of a set of genes involved in different processes such as proliferation, 
survival and differentiation of cells, as well as factors such as proinflammatory cytokines 
that control immune and inflammatory responses 20. The precise role and mechanism of 
lncTNF is still not known and should be addressed in future studies.
The liver is comprised of four basic cell types: hepatocytes (parenchymal cells), hepatic 
stellate cells (HSCs), Kupffer cells (stellate macrophages) and sinusoidal endothelial cells. 
The focus of this thesis is on understanding lncRNA function in hepatocytes, as they are 
the most abundant cell type in the liver, comprising approximately 80% of the liver’s mass 
and performing the majority of hepatic functions, including those related to metabolism, 
synthesis, detoxification and storage. Moreover, excessive FFA are stored in hepatocytes, 
where they promote lipid toxicity, which causes ballooning and degeneration and eventual 
leads to cell injury and death. Hepatocyte damage stimulates an inflammatory response, 
activating macrophages and hepatic stellate cells 21. Hepatocytes injury also contributes 
to the initiation and progression of fibrosis through complex processes involving nearby 
cells 22. Although the studies described in this thesis are focused on hepatocytes, many 
of the lncRNAs that we detected in the liver may be functional in other liver cell types, 
therefore further investigation in this direction will be essential to better understand 
lncRNA function in NAFLD. 
More recently, a number of different inflammatory mediators released from adipose tissue 
and the liver/gut axis have been implicated in NASH pathogenesis. Thus, a ‘multiple hits’ 
hypothesis involving organ-organ interactions in NASH is also feasible 23. In this model, 
NASH pathogenesis is initiated by triggering of excessive oxidative stress by lipotoxic 
metabolites. This, in turn, drives hepatocyte death, inflammation and fibrosis. Additional 
pathogenic factors from other organs, such as gut-derived endotoxins resulting from 
increased gut permeability and gut dysbiosis and adipokines secreted from adipose tissue, 
are all considered crucial to NASH pathogenesis 24,25. It is therefore essential to consider 
studying lncRNAs in response to various stimuli involved in NASH, which will complement 
the knowledge of FFA- and TNFα- associated lncRNAs described in this thesis. 
Enhancer RNAs are associated with NAFLD
Many functional enhancers can be transcribed to generate non-coding enhancer RNAs 
(eRNAs) that are highly tissue- and context-specific. In chapter 6, we assess the association 
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between eRNA expression levels and NAFLD phenotypes and investigate whether these 
enhancers could control the genes in their vicinity. Many inflammatory genes showed 
co-expression with nearby predicted eRNAs, suggesting that they might be under the 
control of nearby enhancers. We also examine whether the genetic variants associated to 
liver and cardiometabolic traits co-localize, or are in close proximity with, these enhancers 
and if these variants affect the abundance of predicted eRNAs. However, we cannot 
illustrate any causality, nor can we distinguish whether eRNAs are functional products of 
enhancers directly involved in gene regulation or byproducts of enhancer activity that are 
transcribed due to open chromatin. Therefore, all expressed eRNAs in this study represent 
predicted eRNAs through transcription. Further functional study is therefore warranted, 
e.g. CRISPR-based knock-down and/or shRNA-mediated knock-down on the RNA levels 
of enhancers. As enhancer activity is known to be highly cell-type specific and context-
dependent, single-cell analysis would be more powerful in illustrating the mechanism of 
eRNAs. 
Future perspectives to study lncRNA function
The research in this thesis revealed that non-coding RNAs are involved in many pathways 
in the liver and may control several different elements of the liver function. We have 
shown that selected lncRNA candidates play a role in maintaining cellular viability and 
inflammatory pathways and that eRNAs may be involved in regulating genes for liver 
diseases and may mediate genetic susceptibility to complex diseases. However, to gain 
a more complete picture of the role of lncRNAs in liver disease, several challenges and 
bottlenecks need to be overcome. Moreover, moving from identifying associations and 
understanding mechanisms to clinical translation requires several essential steps, which 
I discuss below. 
Cellular localization of lncRNAs
To reveal lncRNA function, one starting point can be analyzing lncRNA localization both 
on the tissue- and subcellular-level. Techniques such as fluorescent in situ hybridization 
(FISH) 26 can provide important insights into the cell types that are important for their 
function and in which subcellular compartment they act. Another strategy may be to 
employ cell fractionation, a process that separates the nuclear and cytoplasmic fractions, 
followed by qRT-PCR to detect enrichment of RNA molecules of interest. The second 
approach was used this thesis to detect cellular localization of lncRNAs (chapter 3, 4 
and 5). We found the three selected lncRNA candidates to be enriched in the cytoplasm, 
therefore one hypothesis may be that these lncRNAs are responsible for regulating post-
transcriptional processes such as mRNA stability/ turnover and translational control. 
However, if a lncRNA is found in the cytoplasm, the first thing to check is whether it is 
associated with ribosomes and may be translated 27–29. Studies have reported ribosome 
profiling analysis to assess to what extent ncRNAs are translated into small proteins or 
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peptides 30. Ribosome profiling uses high-throughput sequencing to provide a global 
measurement of RNAs that are associated with ribosomes within cells to monitor RNA 
translation. However, this technique does not necessarily distinguish between RNAs that 
are truly translated and those that are just bound to ribosomes. In addition, most of the 
peptides translated from lncRNAs are likely to be highly unstable and nonfunctional 
30. Therefore, it remains to be discovered which lncRNAs are truly non-coding, and this 
requires development of novel techniques. It will also be interesting to uncover whether 
these concepts are general or cell-specific, and if translated lncRNAs are regulated in a 
pathophysiological manner.
Cytoplasmic lncRNAs can bind to mRNAs, leading to the recruitment of RNA-binding 
proteins (RBPs) that promote decay, RBPs that suppress translation, or factors that initiate 
translation. These processes may also be mediated via lncRNA-mRNA complexes that 
prevent microRNAs from binding to their target mRNAs 31. Therefore, to understanding 
the mechanism of action of lncRNAs, it is important to identify their interacting molecules. 
In the past few years, several methods have been proposed to detect such interactions 
between lncRNAs and proteins or nucleic acids. These include RNA-protein (crosslinking 
immunoprecipitation, CLIP) 32, RNA–RNA (crosslinking analysis of synthetic hybrids, 
CLASH) 33 or RNA-DNA (CHART 34,35 and ChIRP 36) interaction assays. However, due to 
the nature of the RNA molecule, many of these assays can detect non-specific binding, 
therefore including appropriate controls is essential 37.  
Manipulating lncRNA expression levels
To understand the functional roles of lncRNAs in the cell, scientists have applied similar 
strategies to those used to understand mRNA of protein coding genes, including gene 
modification, overexpression, knockdown or knockout strategies. 
RNA interference (RNAi) is one widely used method for gene silencing. In RNAi, expression 
of a target gene is silenced by selective inactivation of its corresponding RNA molecule 
by double-stranded RNA (dsRNA) 38,39. By using small interfering RNAs (siRNAs) or short 
hairpin RNAs (shRNAs), the silencing mechanism is established via post-transcriptional 
degradation of a target RNA molecule. shRNAs have several advantages over siRNAs, 
including that their mechanism of action is significantly more efficient as they use the 
miRNA pathway and that they can be continuously synthetized by the host cell and, 
therefore, their effect should last much longer 40,41. In this thesis, we used shRNA-mediated 
gene silencing to downregulate gene expression of selected lncRNA candidates: LIVAR 
(chapter 3), HNF4A-AS (chapter 4) and lncTNF (chapter 5). All three lncRNAs showed 
enrichment in the cytoplasm, showing that an RNAi strategy was suitable here as this 
method is useful to study trans-acting cytoplasmic lncRNAs. However, we had to take into 
consideration that RNAi-based gene silencing acts post-transcriptionally, and therefore 
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does not block the act of transcription. This may be important for lncRNAs, which may 
produce their effects via the mechanism of transcription. 
The discovery of short palindromic repeats (CRISPR)-associated protein 9 (Cas9) system 
has shepherded in a new era in targeted genome editing. Targeting of Cas9 to a region of 
interest results in a blunt double-stranded DNA break, which is subsequently repaired by 
small deletions or insertions 42. While these small changes are sufficient to disrupt protein-
coding gene function, they may not necessarily lead to functional loss of a given non-
coding gene because they lack an open reading frame 43. Therefore, several adaptations 
of this tool include deletion of the full-length lncRNA locus or its promoter sequence, 
mutation of putative functional domains (if known), or targeted interruption between the 
promoter and the RNA sequence. However, such large deletions may result in removal 
of regulatory regions, thus they may introduce many changes that are irrelevant to the 
function of the lncRNA under study. For example, promoter deletion may disrupt the 
expression level of protein-coding transcripts with which lncRNAs share a bidirectional 
promoter. Additionally, many lncRNAs initiate within enhancers 44, and in these cases 
disruption of the lncRNA promoter could cause unintended changes in gene expression. 
In addition, many regulatory regions are found through the gene body, so deletion of a 
lncRNA genomic locus will not cleanly separate out the role of the lncRNA from the role of 
other functional elements locating within the overlapping DNA region. These examples 
clearly highlight the importance of minimizing the removal/reorganization of regulatory 
factor binding sites or other regulatory elements within the DNA and of controlling for the 
addition of novel binding sites. 
To overcome these issues, scientists have developed a CRISPR interference (CRISPRi) 
system that enables recruitment of transcriptional activation or repression domains to 
defined sites within the genome to modulate transcription 45,46. One application of CRISPRi 
technology allows transcriptional repression of any gene via targeted recruitment of the 
nuclease-dead dCas9-KRAB repressor fusion protein to the transcription start site (TSS) 
by a single guide RNA (sgRNA) 46. This technique is highly precise as it acts only within 
a small window (1 kb) around the targeted TSS, and dCas9 confines only 23 base pairs 
of the targeted DNA strand 47,48. CRISPRi catalyzes repressive chromatin modification 
H3K9me3, which is highly specific with few or no off-target effects 46,49–51. Finally, these 
methods can be used to design CRISPRi libraries targeting thousands of lncRNA loci to 
screen for functional lncRNAs. The CRISPRi Non-Coding Library (CRiNCL) was designed 
in this way; it is a systematic screening approach that targets 16,401 lncRNA genes, each 
with 10 sgRNAs per TSS, followed by a pooled screening to identify lncRNA genes that 
modify robust cell growth in seven human cell lines 52. Therefore, one direction for further 
studies examining the NASH-associated lncRNAs reported in this thesis (chapter 4) and 
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FFA- and TNFα- associated lncRNAs in HepG2 cells (chapter 5) may include such a high-
throughput CRISPRi-based approach to screen for functional lncRNAs.
Clinical implication of lncRNAs in the liver
Abnormal expression of lncRNAs in the liver may affect many downstream genes and 
related signaling pathways, ultimately leading to disease. Therefore, manipulating 
the expression levels of these lncRNAs may be an important clinical tool. Furthermore, 
lncRNAs have cell- or tissue-specific expression, which means they harbor great potential 
as therapeutic targets. Oligonucleotide-based therapeutics have been proposed for post-
transcriptional targeting of any RNA of interest 53,54. These nucleic acid-based drugs (e.g. 
siRNAs, antisense oligonucleotides (ASO)) can target any unique region of the human 
transcriptome and, importantly, provide the ability to target the ‘undruggable’ portions of 
the genome. Although many questions and challenges remain to be addressed, nucleic 
acid therapeutics have been quite successful and lncRNA-targeted therapy has already 
been proposed in cancer. In this way, upregulated lncRNAs can be directly targeted by 
their specific siRNAs or ASO 55,56. For example, targeting of MALAT1 by siRNAs in human 
prostate cancer cell lines resulted in inhibition of cell growth, invasion and migration, 
and induced cell-cycle arrest 57. Furthermore, using genome editing methods such as 
CRISPR/Cas9, it is possible to achieve transcriptional silencing of lncRNA-expressing 
loci using CRISPRi 52. Targeted vector-based delivery has been proposed as a new 
approach to lncRNA-based therapy. In this way, introduction of tumor suppressor MEG3 
into hepatocellular carcinoma tumors effectively induced apoptosis in hepatocellular 
carcinoma cells 58. Although lncRNAs present important candidate therapeutic targets in 
cancer and other pathologies, more studies are required to better understand the biology 
of lncRNAs and lncRNA-targeting drugs. In this direction, the lncRNAs detected in this 
thesis may be a potential target for further treatment developments in NAFLD. Therefore, 
understanding lncRNA mechanisms of action and further functional studies on preclinical 
models will greatly promote the development of lncRNA-based diagnosis and therapy for 
various disorders including NAFLD.
In summary, the findings reported in this thesis extend our current knowledge and 
understanding of the molecular mechanisms of NAFLD by showing that non-coding RNAs 
may control several important biological functions. As a consequence, non-coding RNA 
deregulation can have a severe impact on cellular behavior, and thereby lead to disease. 
As research in this area moves forward, new causal mechanisms involving functional 
roles of non-coding RNAs are likely to be defined. Novel concepts related to lncRNAs and 
liver physiology have been successfully integrated into the drug development process 
to develop effective therapies. Continued efforts are still needed to further expand the 
current knowledge in order to develop lncRNA-based therapeutics for the treatment of 
chronic liver diseases. 
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